Ovascience Cultura de la Empresa

Dr. Jonathan L. Tilly, also known as Job, Ph.D., is a Co-Founder of OvaScience, Inc. Dr. Tilly joined the faculty of Johns Hopkins University as an Assistant Professor in 1993, and moved to Massachusetts General Hospital (MGH) in 1995 as Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School (HMS) to direct the newly-created Vincent Center for Reproductive Biology at MGH. He was promoted to Professor of Obstetrics, Gynecology and Reproductive Biology at HMS in 2009. Dr. Tilly's primary area of research is on the development of methods for preserving or reviving fertility and prolonging or restoring ovarian function in young girls and women. Dr. Tilly served as Co-Chairman of The Scientific Advisory Board at OvaScience, Inc. Dr. Tilly has been an Advisor of OvaScience Inc., since July 15, 2011 and served as its Director from July 2011 to January 6, 2014. Dr. Tilly has taken a much different approach to new methods of fertility preservation and extension of ovarian function based on his discovery of a rare population of stem cells in the ovaries of adult mice that are capable of generating new eggs. Following publication of this ground-breaking study in Nature in 2004, Dr. Tilly re-focused his entire lab on characterization of oocyte-producing stem cells to demonstrate that ovarian failure can be reversed through stem cell-based technologies. In addition to this line of work, Dr. Tilly is an authority on how dietary caloric restriction (CR) and CR mimetics can be used to remarkably offset the negative impact of aging on ovarian function and egg quality. Dr. Tilly is a member of the National Scientific Advisory Committee of the American Federation for Aging Research and is the recipient of a 10-year MERIT Award from the National Institute on Aging of the National Institutes of Health. His work has been published in 113 original research articles, 20 reviews, 14 editorials, 19 book chapters and two edited books. He is the recipient of three issued patents, including one for his discovery of oocyte-producing stem cells, and has three other patent applications under examination. Dr. Tilly obtained his Ph.D. degree in 1990, and then completed postdoctoral training at the University of California-San Diego School of Medicine and Stanford University Medical Center.

Mr. Jonathan Gillis has been Principal Financial Officer and Principal Accounting Officer at OvaScience, Inc. since June 21, 2017 and serves as its Vice President of Finance. Mr. Gillis served as Assistant Controller at OvaScience from June 2013 to January 2014 and also served as its Controller from January 2014 to August 2015 and Senior Director of Global Finance & Operations from August 2015 to June 2017. Prior to joining the Company, Mr. Gillis was Senior Manager of External Reporting and Compliance at GFI Software, Inc. from January 2013 to June 2013. He served as Assistant Controller at Aspen Aerogels, Inc. from May 2012 to January 2013. Mr. Gillis worked at Birch Hill Partners, LLC and PricewaterhouseCoopers, LLP.

Dr. Michelle Dipp, M.D., Ph.D., has been Managing Director of General Atlantic LLC since October 10, 2017. Dr. Dipp co-founded OvaScience, Inc. in April 2011 and has been its Advisor since September 1, 2017. She co-founded Axial Biotherapeutics, Inc and served as founding Chief Executive Officer. Dr. Dipp is a Co-Founder of Verastem, Inc., Alnara Pharmaceuticals and FlexPharma. She is the Co-Founder and Advisor at Flex Pharma, Inc. She is also the Founder and Partner at Longwood Founders Management, LLC. She is a Co-Founder of Longwood Founders Fund, L.P. She is a Partner of Longwood Fund. Dr. Dipp served as Corporate Secretary of OvaScience, Inc. until September 1, 2017 and served as its Chief Executive Officer from June 2011 to July 01, 2016 and President from September 2011 to December 2014. Dr. Dipp served as Executive Chairman of OvaScience, Inc from January 6, 2016 to September 01, 2017 and also served as its Acting President. She served as a Senior Vice President and Head of Centre of Excellence for External Drug Discovery (CEEDD) at GlaxoSmithKline. She served as an Associate Director of Strategic Development and Vice President of Corporate Development at Sirtris Pharmaceuticals, Inc. Dr. Dipp led the successful acquisition of Sirtris by GSK in June 2008 for $720 million. Before joining Sirtris as a founding employee and a co-founder, she worked in healthcare private equity at The Wellcome Trust. Dr. Dipp has been Chairman of the Board and Director at Axial Biotherapeutics, Inc. since November 30, 2016. She serves on the Beth Israel Deaconess Medical Center Board of Trustees, the Beth Israel Institute for RNA Medicine Advisory Board, the Boston Symphony Orchestra Board of Overseers and the Board of Directors of the City on a Hill Charter School in Roxbury. She serves on the Biotechnology Industry Organization's (BIO) Emerging Companies Governing Board, New England Venture Capital Association (NEVCA) Board and MassBio Advisory Board. She serves on the Board of Colorescience. She serves as a Board Observer of Bicycle Therapeutics. Dr. Dipp served as Director of OvaScience, Inc. from July 2011 to September 1, 2017. In 2015, Dr. Dipp was elected to join the World Economic Forum's Young Global Leaders and was named to Fortune magazine's 40 Under 40 list. Dr. Dipp is the women's health Contributor for Thrive Global. She did her post-doctoral research in the departments of Pharmacology and Cardiothoracic Surgery, John Radcliffe Hospital, Oxford. Dr. Dipp holds a BM, BCh (MD equivalent) from the Oxford University Medical School and a DPhil (PhD equivalent) in Physiology from University of Oxford.

Dr. Gabriel M. Cohn, M.D., has been Head of Global Clinical & Medical Affairs and Vice President at OvaScience, Inc. since April 2016 and since June 2015 respectively and served as its Head of Medical Affairs and Translational Medicine from June 2015 to March 2016. Dr. Cohn is a Board-certified OB/GYN and Clinical Geneticist, who served as the Chief of the Division of Clinical and Reproductive Genetics Department at Baystate Medical Center and the Director of Reproductive Genetics, Division of Maternal Fetal Medicine at SUNY Health Science Center (HSC) at Syracuse. He joined OvaScience from Shire, where he held roles that included Medical Director and Interim Medical Lead for the Gaucher Disease Franchise and the Senior Medical Director of Clinical Sciences. In these roles, he was responsible for activities such as medical affairs''?? educational programs, publication strategy, key opinion leader engagement, patient registry strategy and asset evaluation. Dr. Cohn holds an M.D. from SUNY HSC at Syracuse, School of Medicine and an M.B.A. from the Isenberg School of Management, University of Massachusetts. He completed his OB/GYN residency at SUNY HSC at Syracuse and his clinical genetics fellowship at the National Institutes of Health.

Dr. James D. Luterman, also known as Jim, Ph.D., has been Executive Vice President of Research and Development at OvaScience, Inc. since August 26, 2016. Dr. Luterman served as Senior Vice President of Research & Development at OvaScience, Inc. since March 31, 2016 until August 26, 2016. Dr. Luterman joined OvaScience in January 2014 and served as its Vice President of Research & Development. He has over 20 years of industry experience. Dr. Luterman served in various positions at Shire Human Genetic Therapies, including Early Development Team Leader and Senior Director Strategic Planning and Program Management. He also worked at Biogen and Decision Resources Group. Dr. Luterman was a postdoctoral fellow at Mount Sinai School of Medicine. He holds a B.A. in Biology and Psychology from Bucknell University and a Ph.D. in Behavioral and Neural Sciences from Rutgers, the State University of New Jersey.

Louis Villalba serves as the Executive Vice President of OvaScience. Louis started at OvaScience in Dec of 2016. Louis currently resides in the San Francisco Bay Area.

Chris Bleck serves as the Chief Operating Officer of OvaScience. Chris started at OvaScience in Nov of 2011. Chris currently resides in the Greater Boston Area.